Senseonics Offers a Once-a-Year Implant Option for CGMs

 

“We have the best-in-class accuracy, especially at the low end for predicting hypoglycemia, which is really important because of that light generation,” says Senseonics CEO Tim Goodnow, explaining the company’s implantable Eversense continuous glucose monitor (CGM) to Bloomberg Intelligence. Goodnow is referring to Eversense’s micro-fluorometer technology, which generates light to measure glucose levels. “And importantly, the accuracy has to be maintained on day 360.” In this Vanguards of Healthcare episode, Goodnow sits down with BI analystMatt Henriksson for an in-depth interview about the design of the implantable Eversense sensor and how it can accurately measure glucose for up to a year. He also highlights the key developments in its pipeline to add battery power and Bluetooth directly to the sensor, eliminating the need for a transmitter.

Loading transcript

Vanguards of Healthcare by Bloomberg Intelligence

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought lea… 

Social links

Follow podcast